Transcript PPT - Medifluidics

Electronic Injector
for use with most standard and
prefilled syringes
Copyright© September 2015
THE PROBLEM:
No one likes injections or needles
7-22 % of the public is needle phobic
For these patients, the prospect of injecting causes:
a sick feeling and physical autonomic reactions,
resulting in missed injections,
resulting in poor treatment of underlying medical problems,
resulting in lowered quality of life and medical complications.
Self-injection requires skill, fortitude, and involves an amount of risk*
*(improper positioning can cause bruising, tissue damage, incorrect dosage, and bent needles
THE SOLUTION: InnoJect Electronic Injector
✓ our technology makes it easy to perform self-injection
✓ simplifies and improves the injection process experience
VISUAL:
●
Hides the needle and syringe inside the injector applicator
PHYSICAL:
●
Provides tonal biofeedback for appropriate steadiness of orientation on skin surface
●
Contains patent pending pain suppression technology
AUDIO:
●
Spoken instructions guide the user thru each step of injection (most languages are
available)
USABILITY:
●
Gentle needle insertion, dispensing of medication, and needle retraction via electronic
motion control
●
Reminder timer for next injection (ringtone)
THESE:
Standard Syringes and
Prefilled-Syringes
Go In here
Patent Pending
Current Products on the Market & Weakness
•
•
•
•
Insulin Pens (mechanical, manual needle insertion)
Autoinjectors (spring fired, preloaded, single use, expensive)
Autoinjectors (spring fired, loads limited range of syringes)
Jet Injectors (not painless, limited to drugs approved for jet)
Innoject is a New Market:
• Home administered drugs which have one of the following:
✓ no injection aid
✓ requires a larger needle than other injection devices can
accommodate
✓ available injection aid is painful and scary to use
These administered drugs totaled 13.7 million prescriptions in U.S. in 2007 (see next slide).
INNOJECT: MARKET ANALYSIS & TRENDS IN US
TOTAL ACCESSIBLE MARKET: 17.5 million projected customers
•56 million self-injectable prescriptions in the U.S. annual§
•35 million self-injectable prescriptions applicable to InnoJect usage*
•17.5 million potential customers per annum**
INITIAL TARGET MARKET: 68,000 projected customers per annum
•13.7 million prescriptions are prime candidates for this market space***
•6.8 million projected customers available for capture**
•1% capture rate = 68,000 InnoJects sold per annum U.S.
§ 2007 NAMCS Data (National Ambulatory Medical Care Survey) and Insurance Survey for Drugs for
Home Use by Blue Cross and Blue Shields 2007.
*A percentage of the prescriptions for each drug applicable to our device, according to its specifics,
is weighted and used to give a potential market.
**Assumes that half the prescriptions are refills.
***Initial projected market share is based upon the number of pharmaceutical drugs most likely
prescribed along with the InnoJect device, is weighted and number calculated.
Future Target Markets
• Medical facilities where NextGEN InnoJect model is utilized
with multiple patients (1 device to multiple patients)
• International (underdeveloped countries) pharmaceutical
drugs administered in treatment centers
• Immunizations stations
• Prefilled syringes NOT currently compatible with initial
InnoJect model*
* 2.5 billion prefilled syringes used worldwide in 2011.
Market Entry Scenario
Contracts with the industry principle(s) for marketing function may be:
– distributors
– syringe manufacturers
– drug manufacturers who wants to distinguish themselves by solving
the “self-injection” problem for their product.
Market Entrance Scenario
1. Self-Injectable drugs are prescribed by a physician.
2. The physician sees our client, the patient.
3. InnoJect (Class II medical device) requires prescription.
4. The InnoJect turns a standard syringe or prefilled syringe into an
“autoinjector” with finesse, effectively making the prospect of “self
injection” an easy and much less scary task.
5. Doctor solves patient’s self-injection problem by prescribing the
InnoJect to the client along with prescribed self-injectable drug.
6. Client’s costs covered by insurance company (part of marketing plan).
Model Production Timeline
• 1st Model -(Year 1): BASIC unit (home use*)
(Entry point into market. Basis of Medicare Version.)
• 2nd Model - (Year 2): BASIC unit Plus*
(New feature added: pain suppression technology )
• 3rd Model - (Year 4): Multiple patient unit
with twist-off needle shield. (Disposable sterile
needle shields allow for repeat use on multiple patients.
Provides repeat sales of disposable needle shields.)
*Basic unit - home use/plus pain suppression models: patient purchases 1 unit that is reusable
for multiple injections... not multiple patients.
Facts about the Fear of Needles
• Approximately 20 percent of the general population has
some degree of fear associated with needles and injections.
• As much as 10 percent of people suffer from a phobia called
trypanophobia, which is a fear of needles and injections.
• Traumatic experiences in childhood form the foundation of
these fears—like seeing an older sibling cry when getting their
shots.
• Of those who have a fear of needles, at least 20 percent
avoid medical treatment as a result.
• The fear of needles is both a learned and an inherited
condition. A fairly small number inherit a fear of needles, but
most people acquire needle phobia around age four to six.
reference: Healthline.com
info@medifluidics
Copyright© September 2015